Pharmaceutical

Repligen

$216.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$5.52 (-2.48%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Repligen and other stocks, options, and ETFs commission-free!

About RGEN

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA. The listed name for RGEN is Repligen Corporation Common Stock.

CEO
Tony J. Hunt
Employees
761
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
11.73B
Price-Earnings Ratio
261.97
Dividend Yield
—
Average Volume
442.90K
High Today
$226.75
Low Today
$212.51
Open Price
$223.85
Volume
502.69K
52 Week High
$226.75
52 Week Low
$78.41

Collections

RGEN Earnings

$0.00
$0.14
$0.28
$0.42
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 18, Pre-Market

You May Also Like

FTOCW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure